Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.

A positive trend was observed between AUC 0−t , AUC 0−inf , and C max and aPTT for both participants with moderate hepatic impairment and normal hepatic function (Figure 2c ).

also in 11,005 other papers